Roche's Alzheimer's drug spurred biomarker changes but no cognitive impact — paper; vTv out-licenses former lead program
More than a year ago, Roche and Eli Lilly were forced to contend with a Phase II/III failure of their respective Alzheimer’s drugs. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
